CLINICAL TRIALS PROFILE FOR PROCHLORPERAZINE

All Clinical Trials for Prochlorperazine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00020657 ↗	Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer	Completed	National Cancer Institute (NCI)	Phase 3	2001-07-01	RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in preventing delayed nausea after chemotherapy in patients who have cancer.
NCT00020657 ↗	Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer	Completed	Gary Morrow	Phase 3	2001-07-01	RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in preventing delayed nausea after chemotherapy in patients who have cancer.
NCT00122278 ↗	Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines	Completed	Montefiore Medical Center	Phase 3	2005-07-01	Migraines are a specific type of headache that frequently recur and are very painful. Although there are many medications that are effective against migraines, none of these medications cure 100% of migraines. Another problem with migraines is that although many times they get better after intravenous (IV) treatment in the emergency room (ER), about 1/3 of the time migraines recur the next day. The purpose of this research project is to see if adding a medication called dexamethasone to standard ER therapy will help patients get better quicker and stay pain-free more often than if they receive placebo.
NCT00149578 ↗	A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer	Unknown status	Chang Gung Memorial Hospital	Phase 2	2004-10-01	Induction chemotherapy will be administered every 2 weeks for 6 cycles (about 3 months). Patients who have radiological evidence of progressive disease will be shifted to salvage chemotherapy. Patients who have responsive or stable disease after induction chemotherapy will receive concurrent chemoradiotherapy 3-4 weeks after the last dose of induction chemotherapy. Surgical evaluation will be performed 4-6 weeks after the completion of chemoradiotherapy. Patients who have resectable disease will undergo surgical resection. Postoperative adjuvant chemotherapy with GOFL for 6 cycles will be given for those who have curative resection. Patients who still have unresectable disease or non-curative resection will receive systemic chemotherapy of GOFL till disease progression or unacceptable toxicity.
NCT00149578 ↗	A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer	Unknown status	China Medical University Hospital	Phase 2	2004-10-01	Induction chemotherapy will be administered every 2 weeks for 6 cycles (about 3 months). Patients who have radiological evidence of progressive disease will be shifted to salvage chemotherapy. Patients who have responsive or stable disease after induction chemotherapy will receive concurrent chemoradiotherapy 3-4 weeks after the last dose of induction chemotherapy. Surgical evaluation will be performed 4-6 weeks after the completion of chemoradiotherapy. Patients who have resectable disease will undergo surgical resection. Postoperative adjuvant chemotherapy with GOFL for 6 cycles will be given for those who have curative resection. Patients who still have unresectable disease or non-curative resection will receive systemic chemotherapy of GOFL till disease progression or unacceptable toxicity.

Clinical Trial Conditions for Prochlorperazine

Condition Name

Condition Name for Prochlorperazine
Intervention	Trials
Migraine	8
Headache	6
Nausea	5
Emesis	2

Condition MeSH

Condition MeSH for Prochlorperazine
Intervention	Trials
Migraine Disorders	18
Headache	17
Emergencies	10
Nausea	9

Clinical Trial Locations for Prochlorperazine

Trials by Country

Trials by Country for Prochlorperazine
Location	Trials
United States	109
Canada	4
Italy	2
Taiwan	1

Trials by US State

Trials by US State for Prochlorperazine
Location	Trials
New York	12
Ohio	8
Michigan	6
Texas	5
North Carolina	5

Clinical Trial Progress for Prochlorperazine

Clinical Trial Phase

Clinical Trial Phase for Prochlorperazine
Clinical Trial Phase	Trials
Phase 4	12
Phase 3	11
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for Prochlorperazine
Clinical Trial Phase	Trials
Completed	24
Terminated	8
Recruiting	7

Clinical Trial Sponsors for Prochlorperazine

Sponsor Name

Sponsor Name for Prochlorperazine
Sponsor	Trials
National Cancer Institute (NCI)	4
Montefiore Medical Center	4
Alexza Pharmaceuticals, Inc.	4

Sponsor Type

Sponsor Type for Prochlorperazine
Sponsor	Trials
Other	56
Industry	16
NIH	6

Prochlorperazine: A Versatile Drug with Promising Clinical Trials and Market Projections

Introduction

Prochlorperazine, a medication belonging to the phenothiazine class of antipsychotic drugs, has been widely used for managing severe nausea and vomiting, as well as certain mental health disorders. Recent research and clinical trials have unveiled new potential uses for this drug, making it a subject of significant interest in both medical and market contexts.

Clinical Trials and New Indications

Cancer Treatment

A groundbreaking study published in Cell has identified a new drug combination that involves prochlorperazine (known as Stemetil in Australia) to enhance cancer treatments. Led by Associate Professor Fiona Simpson from the University of Queensland, the research shows that prochlorperazine can alter the surface of tumor cells, making them more susceptible to the immune system and existing cancer drugs like cetuximab, trastuzumab, and avelumab. This combination has shown remarkable results in mice and initial human trials, including the development of long-term immunity against certain cancers[1].

Antiviral Properties

Prochlorperazine has also been found to have antiviral properties, particularly against the dengue virus. A study revealed that prochlorperazine can block dengue virus infection by targeting viral binding and entry mechanisms. This discovery highlights the potential of drug repurposing in accelerating the development of antiviral treatments[4].

Market Analysis

Current Market Size and Growth

The global prochlorperazine maleate market is valued at approximately US$ 1.46 billion in 2023 and is projected to reach US$ 1.85 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.4% during this period. This growth is driven by the drug's established efficacy in managing nausea and vomiting, particularly in conditions such as chemotherapy, postoperative procedures, and mental health disorders[2][5].

Market Drivers

Several factors are driving the growth of the prochlorperazine maleate market:

• Increasing Prevalence of Chronic Diseases: The rising prevalence of chronic diseases and an aging population are increasing the demand for antiemetic therapies.
• Patient Awareness and Treatment Seeking: Growing patient awareness and the willingness to seek out effective treatments are contributing to market growth.
• Versatility in Treatment: Prochlorperazine's versatility in treating multiple conditions across various medical specialties, including oncology, gastroenterology, and neurology, further expands its market potential[2][5].

Regional Insights

The North American region holds a significant revenue share in the global prochlorperazine maleate market. This is due to the high prevalence of conditions requiring antiemetic therapy and the advanced healthcare infrastructure in the region[5].

Market Segmentation and Trends

Dosage Forms and Administration

Prochlorperazine maleate is available in various forms, including oral tablets, rectal suppositories, and injectable formulations. This flexibility in administration caters to different patient needs and preferences, contributing to its widespread use[5].

Patient-Centered Care

There is a growing trend towards patient-centered care, with healthcare practitioners and pharmaceutical companies focusing on patient preferences, needs, and treatment outcomes. This trend is driving the development of patient-friendly formulations and personalized treatment approaches, which are expected to further boost the market for prochlorperazine maleate[3].

Challenges and Limitations

Safety Issues and Side Effects

Despite its potential, the prochlorperazine maleate market faces challenges related to safety issues and negative side effects. These concerns can hamper market growth and necessitate careful monitoring and management[2][5].

Supply Chain Disruptions

The global pharmaceutical supply chain, including that of prochlorperazine maleate, faced disruptions during the early phases of the COVID-19 pandemic. Such disruptions can impact the availability of the drug and affect market growth[3].

Future Prospects and Research

Combination Therapies

The investigation of combination therapies involving prochlorperazine maleate is expected to create new opportunities for market growth. The success of the combination with existing cancer drugs, as seen in recent clinical trials, underscores the potential for such approaches[1][2].

Enhanced Formulations and New Indications

Ongoing research and development efforts aim to improve the drug's formulation, enhance patient compliance, and explore new therapeutic indications. These initiatives are crucial for expanding the commercial potential of prochlorperazine maleate[3][5].

Key Takeaways

• Clinical Trials: Prochlorperazine has shown promising results in clinical trials for cancer treatment and antiviral applications.
• Market Growth: The global prochlorperazine maleate market is expected to grow at a CAGR of 3.4% from 2023 to 2030.
• Market Drivers: Increasing prevalence of chronic diseases, patient awareness, and the drug's versatility are key drivers.
• Regional Insights: North America holds a significant revenue share in the global market.
• Challenges: Safety issues and supply chain disruptions are potential limitations.

FAQs

What are the primary uses of prochlorperazine maleate?

Prochlorperazine maleate is primarily used for managing severe nausea and vomiting, as well as treating symptoms of schizophrenia and other mental health disorders.

How does prochlorperazine maleate work?

Prochlorperazine maleate works by blocking dopamine receptors in the brain, thereby reducing the sensations of nausea and vomiting.

What are the new potential uses of prochlorperazine maleate?

Recent research has identified potential new uses for prochlorperazine maleate, including enhancing cancer treatments and exhibiting antiviral properties against the dengue virus.

What is the projected market size of prochlorperazine maleate by 2030?

The global prochlorperazine maleate market is expected to reach US$ 1.85 billion by 2030.

What are the main challenges facing the prochlorperazine maleate market?

The main challenges include safety issues and negative side effects, as well as potential supply chain disruptions.

Sources

1. University of Queensland: "New drug combination could support better cancer treatments" - March 6, 2020.
2. Coherent Market Insights: "Prochlorperazine Maleate Market, By Indication, By Dosage Form" - 2023.
3. InsightAce Analytic: "Prochlorperazine Maleate Market Share, Size, Growth and Forecast" - November 11, 2024.
4. Oxford Academic: "Repurposing of Prochlorperazine for Use Against Dengue Virus" - 2020.
5. Coherent Market Insights: "Prochlorperazine Maleate Market Size and Forecast to 2030" - 2023.